- Home
- RFI vs CLPT Comparison
RFI vs CLPT Comparison
Compare RFI & CLPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFI | CLPT |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 353.5M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | RFI | CLPT |
|---|---|---|
| Price | $11.12 | $12.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 113.5K | ★ 570.9K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,971,000.00 |
| Revenue This Year | N/A | $45.67 |
| Revenue Next Year | N/A | $19.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.78 |
| 52 Week Low | $10.78 | $8.27 |
| 52 Week High | $12.18 | $30.10 |
Technical Indicators
Market Signals| Indicator | RFI | CLPT |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 61.35 |
| Support Level | $10.92 | $10.30 |
| Resistance Level | $11.33 | $13.59 |
| Average True Range (ATR) | 0.16 | 0.96 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 31.35 | 72.32 |
Price Performance
Historical ComparisonAbout RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.